This is a past event. Registration is closed. View other OBN events.
Edouard Alphandery
Président at NanobacterieThe company Nanobacterie develops a cancer treatment using natural iron oxide nano-minerals, called magnetosomes, which are introduced to tumors and heated using various excitation sources (laser, ultrasound, magnetic field). We have demonstrated the full efficacy of our treatment on mice bearing several different types of tumors (prostate, glioblastoma, breast tumors). It leads to full tumor disappearance in all treated mice without tumor regrowth at 6 months. It is also safe, which is due its moderate heating conditions and to the use of completely natural/non-toxic nanoparticles.
The advantages of our treatment lie in the following aspects: i) it does not require general anesthesia and the operation theatre and could therefore potentially be carried out in an ambulatory fashion, ii) it is characterized by a large benefit/risk ratio, iii) it is of low cost of fabrication.
Our treatment could therefore potentially be made available to the large percentage of cancer patients. We more specially currently focus on the treatment of prostate tumors.
ZAKIA BELAID-SANDAL
CEO/CSO of THERANOVIRTHERANOVIR is a young innovative Health-Tech company of Research and Development of breakthrough therapies with a primary focus on the field of cancer treatment by targeting a platform of signaling pathways regulated by the complex of proteins NRP-1/OBR, newly discovered by the CEO/CSO Dr. Zakia BELAID-SANDAL (PhD).
Imre Berger
CSO at Halo TherapeuticsHalo Therapeutics idevelops and delivers safe, self-administered pan-coronavirus antiviral prophylactics and early-treatments. Based on ground-breaking discovery during the andemic lockdowns, Halo Therapeutics was founded as a University of Bristol spin-out to bring their innovations to patients. Backed by experienced institutional and private investors, Halo Therapeutics is entering clinical trials for their first product, an anitviral spray formula shown to be active against all deadly coronaviruses including SARS,, MERS, SARS-CoV-2, Omicron and Arcturus.
Alan Boyce
CEO of SmartWound LimitedSmartWound is a vesicle based technology that enables the detection of colonizing bacteria in a wound infection.
Mark Chadwick
CEO of NanoveryNanovery is challenging the dominance of PCR (US$37Bn market including COVID) for the detection of nucleic acids. We use DNA nanorobots in a simple, single step test without enzymes or temperature cycling. The company recently raised a total of £1.85m and has about a 15-month runway (without commercial deals).
Sarah Cole
Chief Operations Officer at SENISCA LtdSENISCA, an award-winning biotech, has identified a new, druggable cause of cellular ageing: RNA splicing dysregulation. SENISCA is raising £7M to develop senotherapeutics that target splicing dysregulation and result in cellular rejuvenation by attenuating senescence. With broad applicability, SENISCA’s technology targets the causes, not simply the consequences, of cellular ageing.
Sian Farrell
CEO of StimOxyGenStimOxyGen is an innovative biotech company focused on overcoming tumour hypoxia (lack of oxygen). Our proprietary technology generates oxygen within tumours to improve the efficacy of cancer therapies, particularly radiotherapy. With streamlined administration and diverse pipeline applications, StimOxyGen aims to make a significant impact in the global fight against cancer.
Athan Fox
CEO of 17CicadaOur aim is to make industry sustainable and regenerative. We do this by manufacturing products in living cells – the ultimate green factory.
Our products include commodity and specialty chemicals, including building blocks for polymers, textiles and cosmetics. Our unique IP eliminates bottlenecks and turns carbon dioxide and waste into products.
Teo Garcia-Millan
CEO of CdotBioCDotBio is an early-stage biotech spin-out building a technological and business opportunity from University of Bristol research. The company’s objective is to develop its proprietary technology for the flexible transformation of plants, achieved through targeted and reversible expression of genes. The mechanism for this is through the delivery of attached pieces of genetic material to tailored carbon nanocarriers in plant cells.
Nick Gompertz
CEO & Founder of EarSwitch LtdEarSwitch®️ is a startup empowering new ways for people to connect with the world and personal health through in-ear biometric control and sensor technology.
Incorporated in 2019, we initially focused on very specific applications for motor neurone disease (MND) and cerebral palsy. Applications now include complex hands-free control, biometric and medical monitoring.
Andrew Guo
Founder of BioMavericksOur company, BioMavericks, is an early-stage biotech startup, which was founded in 2021. We have made significant progress since our foundation. With our focus on developing an in vitro diagnostic urine test for pancreatic cancer, we have secured pre-seed grant funding and reached a promising proof-of-concept stage. I believe our progress thus far underlines our commitment and potential for impact in the cancer diagnostic field.
Andrew Halliday
Co-Founder and Joint Managing Director of Personalised Diagnostics LimitedAn agile Software as a Service (SaaS) company, developing sophisticated and tailored cloud-based software solutions. Our mission is to continually enhance the collection, storage, interpretation and delivery of health and veterinary data, to drive One Health benefits.
Victor Harabari
CEO of CardioCrown LimitedCardioCrown is developing a technology that will enable stroke patients to take control of their rehabilitation. With our innovative product, NeuroVive, patients can benefit from the combined power of Virtual Reality, Artificial Intelligence, and Functional Electrical Stimulation to improve their controlled voluntary arm and hand functions. This system also allows patients to track their rehabilitation progress and receive constant feedback and psychological support. Ultimately, NeuroVive aims to revolutionize stroke rehabilitation by bringing it directly to the patient's homes.
Shaun Holt
Founder & Science Director of TRG Natural PharmaceuticalsNew Zealand-based TRG Natural Pharmaceuticals (formerly known as HoneyLab) develop innovative, scientifically-proven natural products which are available to be licensed by international pharmaceutical and consumer health companies. Our products have been shown in phase 3 studies to be safe and effective for conditions such as rosacea, eczema and cold sores.
Ben Hunt
Chief Commercial Officer / Co-founder of SilotonSiloton is a Bristol-based MedTech company using a new technology called photonic integrated circuits (PICs) to compress the gold-standard retinal imaging technique into a portable, inexpensive, and scalable personal device. This will form the basis of a remote monitoring service for patients with chronic back-of-the-eye diseases such as AMD and DME.
Alistair Irvine
CEO of Scarlet TherapeuticsScarlet Therapeutics is a biotechnology company developing transformative cell therapies. Building on more than a decade of world-renowned research in Bristol, UK, the team at Scarlet is pioneering unique technology to harness the potential of blood as medicine, positioning the company to become the global leader in the field of therapeutic red blood cells.
Piotr Jedryszek
Co-founder of Evolvere BiosciencesThe emergence of antimicrobial resistance poses a significant threat to public health worldwide, as bacteria become increasingly resistant to current antibiotic therapies.
We redesign antibacterials for the 21st century through a platform that rapidly generates therapeutics engineered to minimise the emergence of resistance, with minimal side effects and low-dose pharmacokinetics.
Jack Kennefick
CEO of TagomicsTagomics have developed a ground-breaking, multi-omic, biomarker discovery platform which offers a step change in the development of genomics-based diagnostic assays. The company’s proprietary epigenetics driven platform and advanced machine learning approaches seamlessly integrate with standard clinical workflows to provide unparalleled access to disease associated biomarkers for earlier diagnosis.
Kaido Kurrikoff
CEO of VectiopepVectiopep has developed a technology that transports therapeutic mRNA into the patients' immune tissues. This enables new type of cancer immunotherapy. Our uniqueness is the ability to specifically deliver mRNA into the immune cells, which is what enables its use as an immunotherapeutic. The alternative mRNA delivery technology (the LNP) accumulates into off-target tissues and only allows its use for prevention of infections, but not for treatment.
Jonathan Kwok
CEO of InfinitopesInfinitopes is a Cancer Research UK (CRUK) led spinout from Oxford University. We combine world leading expertise in Precision Immunomics antigen discovery, T-cell immunology, biomanufacturing, vaccinology, and oncology clinical trials. Our preclinical vaccines deliver 80% protection, vs control animals dying in three weeks. Lead candidate entering phase I/IIa in 2024.
David Leahy
Executive Chairman at Opportunity Pharma LtdOpportunity Pharma will be the market leader in innovation management of new drug opportunities offering clients and strategic alliance partners, such as global life science investors, pharma and biotech companies, and academic researchers, curated and objective comparisons of new drug investment opportunities. Opportunity Pharma – your investment virtual assistant.
Luca Lipani
CEO of Transdermal Diagnostics LtdTransdermal Diagnostics is a MedTech spin-out from the University of Bath dedicated to developing innovative technologies for non-invasive and real-time biomarker co-monitoring. We aim to reinvent patient care, leading the commercialisation of pioneering wearable devices to improve the diagnosis, management and prevention of diseases and to ensure healthy ageing for everyone.
Neethan Lobo
CEO of Onena MedicinesOnena Medicines is a Basel-based Stanford spinout biopharmaceutical company with a pipeline of first-in-class antibody medicines to treat advanced cancers. Onena’s drugs neutralize novel growth factors called Dual SMAD Inhibiting Proteins, resulting in local environmental cell death signals instructing the cancer cells to reduce metabolism and commit suicide.
Sheena Macpherson
CEO of ADSILICO LIMITEDUniversity of Leeds spin-out, adsilico, is raising £3.5m Seed round to become the world’s first end-to-end provider of in silico trials for the medical device industry, starting with end-to-end virtual populations.
Offering simulation-ready virtual populations to assess safety, efficacy & performance of medical devices; reducing reliance on human/animal testing.
Fiona Marston
CEO of ErebagenErebagen is a synthetic biology company with a proprietary platform to discover optimise & scale-up novel bioactive products & biocatalysts by activating silent microbial gene clusters for Pharma Agbio, Industrial Biotech & other uses
Jim Millen
Chairman at KargeneraKargenera is developing patented NK-cell activating therapeutics which have attracted over £2m of grant funding to date. Our assets target novel activating NK cell receptors that recognise cancer specific ligands. Our lead asset KG001 has great preclinical data showing efficacy in liver and other cancers.
Ryan Pink
CEO of MetaGuideX LtdMetaguidex is an Oxford spinout that has won three accelerators. TRL4 clinically tested cost-effective single blood-biopsy for the early detection of breast, lung and colon cancer (1/3 common cancers) with opportunity for more. For clinical referral decisions and increase early pharma therapeutic market.
Zeke Steer
CEO of Milbotix LtdAround half of people diagnosed with dementia experience challenging behavioural symptoms linked to unmanaged distress. Agitated and aggressive symptoms reduce quality of life for people with dementia and their carers and drive admissions into care homes, costing the UK over £2 billion/year. The Milbotix SmartSocks™ contain comfortable sensors and artificial intelligence (AI) algorithms to alert carers to distress at a much earlier stage, helping to improving wellbeing and prevent escalations in behaviour.
Nigel Stocks
Founder and CTO of SonotuSonotu is dedicated to improving quality of life for people with hearing loss in low to middle income countries, with high-quality, affordable hearing aids. Spun out from the University of Warwick we have re-engineered hearing aid technology, resulting in affordable, certifiable devices that provide the same quality as industry-leading options.
Michael Themis
Chief Scientific Officer at Testavec LimitedTestavec is a spin out from Brunel University
Our target is to become a preeminent testing service for the safety of newly developing Gene therapies and to develop a unique safety testing system for the rapidly growing Car-T cancer therapy market. Exploiting Technology developed with Backing of MRC and major pharma
Dermot Tierney
Co-Founder & Chief Commercial Officer of AMPLYAMPLY Discovery uses machine learning and synthetic biology to mine vast biological datasets to discover novel drug and nutraceutical candidates. Using a proprietary in silico and in vitro platform AMPLY is discovering best-in-class molecules to tackle some of humankind's greatest challenges such as cancer, MDR infections and metabolic diseases.
Gábor Várkonyi
Director of NeuroVLCNeuroVLC is a company that designs wireless neural interfaces for research groups and pharmaceutical companies with the aim of advancing neural technology and improving people's lives.